Recommended Conferences

Fungal Infections and Treatments

Miami, USA

Clinical Microbiology and Infectious Diseases

Miami, USA

Cancer-Treatment and Therapeutics

New York, USA
Related Subjects
 

Current scenario of drug development for leishmaniasis

Author(s): Croft SL, Seifert K, Yardley V

Abstract

As part of research to identify better treatments for VL and cutaneous leishmaniasis (CL), alternative and potentially cheaper formulations of amphotericin B, alklyphosphocholines other than miltefosine and improved formulations of paromomycin for CL have been identified. The process for discovery and development of new antileishmanials would also benefit from improved models, for example, transfected parasites, and non invasive methods of measuring parasite load in rodent models of infection.

Similar Articles

Cutaneous leishmaniasis

Author(s): Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al.